INTRODUCTION
Porphyrias, a group of inherited enzyme disorders of the haem biosynthetic pathway, can be clinically classi®ed into acute and non-acute types. Acute intermittent porphyria (AIP), the most common acute type, is an autosomal dominant disorder caused by a partial de®ciency of porphobilinogen deaminase (PBG-D). 1 Acute attacks of this disease are often precipitated by factors such as drugs, alcohol and caloric deprivation, and early detection is important for the prevention of acute attacks. In asymptomatic carriers the excretion of haem precursors is often normal in between attacks, and diagnosis is based on the determination of erythrocyte PBG-D activity. There is, however, some overlap in erythrocyte PBG-D activity between normal individuals and AIP patients. 2 These limitations prompted us to undertake the study of the mutations responsible for AIP at the DNA level.
To date, about 159 mutations in the PBG-D gene have been reported, including missense, non-sense, frameshift and splice site mutations. 1 These may lead to a decrease in PBG-D levels, the complete absence of detectable protein, the production of an altered but stable protein with abnormal catalytic properties, or an absolutely unstable protein. 1 In this study we compared the biochemical results with the genetic data of a group of patients with AIP.
MATERIALS AND METHODS
From all families attending the Porphyrins and Porphyrias Research Centre, 65 individuals were randomly chosen and genetic analysis was carried out. These individuals belonged to 27 unrelated families (Table 1) .
Urinary aminolaevulinic acid (ALA) and porphobilinogen (PBG) were measured using Ehrlich's reagent as described by Mauzerall and Granick, 3 and erythrocyte PBG-D activity was estimated by a previously described method. 4 Genetic studies were carried out following the methods described by De Siervi et al. 5 Genomic DNA was extracted either from lymphoid cell lines or from peripheral blood using a Puregene DNA isolation kit (Gentra Systems Inc, USA) and ampli®ed by long-range polymerase chain reaction (LR-PCR). Brie¯y, each 40 mL reaction mixture contained 16 pmol of each primer, 200 mM of each deoxy-nucleotide-triphosphate, 1 mmol/L Mg(OAc) 2 , 12 mL of buffer and 1 PCR Gem (Ampliwax, Perkin Elmer, USA). After incubation at 808C for 5 min and 258C for 5 min, 18 mL of buffer, 100 ng of genomic DNA and 4 units of rTth DNA polymerase XL (Gene Amp, Perkin Elmer) were added, to a ®nal volume of 100 mL. After an initial incubation at 948C for 1 min, ampli®cation was carried out in two steps: the ®rst one (16 cycles) was performed with denaturation at 948C for 30 s and annealing and extension at 678C for 5 min. The second step (12 cycles) was performed at 948C for 30 s, and annealing and extension at 678C for 5 min; this time was increased by 15 s/cycle. The ®nal extension step was performed at 728C for 10 min. In this PCR protocol two sets of primers were used to amplify the entire PBG-D gene (10 kb) in two fragments, one including the promoter region to intron 3 (4.5 kb) and the other from exon 2 to exon 15 (5.5 kb). 5 The products obtained were assayed on 1% agarose gels stained with ethidium bromide and puri®ed employing the QIAquick PCR puri®cation kit from QIAGEN, USA.
Each exon and its¯anking intron regions was sequenced using the Amplicycle sequencing kit (Perkin Elmer), following the manufacturer's instructions using 1 mL of [a 33 P] dATP (1 mCi, Dupont). 5 The cycle sequencing reaction (30 cycles) was performed with a denaturation step of 30 s at 958C, annealing 30 s at 608C and extension 60 s at 728C. The reaction was stopped by adding 4.5 mL of stop solution (95% formamide, 20 mmol/L EDTA, 0.05% bromophenol blue and 0.02% xylene cyanole) and, after a denaturation step of 3 min at 948C, samples were loaded in a 4% acrylamide solution (19:1) containing 7 mol/L urea gel preheated at about 508C, and was run at 80 W for different periods depending on both the gene region to be read and the primer used. When the run ®nished, the gel was transferred to a ®lter paper (Whatman no. 3) with a plastic ®lm, dried for 2 h at 80±908C and exposed to an autoradiographic ®lm (Kodak X-OMAT) for 24±48 h. All the mutations were con®rmed as sequencing sense and antisense strands.
RESULTS AND DISCUSSION
Details of the subjects and the results of biochemical and genetic analysis are summarized in Table 1 . Of the 65 subjects studied, the results were concordant in 59, 14 normals and 45 individuals with AIP. Of the 45 individuals diagnosed as having AIP, four (9%) had PBG-D activity above 60 U/mL red blood cells (RBC), the cut-off value used in our laboratory. These subjects were diagnosed as having AIP because they had increased excretion of urinary ALA and PBG, and had developed the characteristic symptoms of the illness. Of the six subjects with discordant results one was diagnosed as having AIP on genetic analysis, and ®ve had biochemical features of AIP. Subject RAV ( Table 1 , family 2), who was diagnosed as normal based on biochemical analysis, had a mutation of 34 P, as did his son GLV, who was symptomatic. Another ®ve patients (ALV, STM, MAV, CLM and MAM, Table 1 ) had PGB-D activity below the cut-off value and had been diagnosed as having latent AIP, but had a normal genetic analysis.
As it is important not to miss any cases of AIP, we consider that genetic analysis is essential, especially in cases where biochemical values are normal.
In the normal group three subjects (NAL, ARE and BEM, Table 1 ) had PBG-D activity below 60 U/mL RBC but they were considered to be normal, taking into account the family history and the values for PBG-D activity in their family. However, this procedure might also lead to misdiagnosis. We conclude that genetic studies make an important contribution to the detection of asymptomatic carriers in affected families.
